



**MYELOMA
CANADA**
MAKING MYELOMA MATTER

British Columbia Approves VELCADE® (bortezomib) for all Transplant Eligible Patients

British Columbia, January, 2012

Multiple myeloma patients in British Columbia now have access to another treatment option following an announcement from the BC Cancer Agency.

Effective January 1st 2012, the eligibility criteria for using VELCADE® (bortezomib) and dexamethasone with or without cyclophosphamide as induction therapy have been expanded to include all multiple myeloma patients who are eligible for autologous stem cell transplantation (ASCT).

For more information on the BC Cancer Agency decision, please [click here](#)